SCHEMBL210990

SCHEMBL210990

CN(C)CCc1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 6/20 0.60
HRH3 Q9Y5N1 4/20 0.60
CHRNA7 P36544 1/20 0.59
LOXL2 Q9Y4K0 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HRH1 P35367 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7092468 0.86 SIGMAR1 (0.53) TAAR1HRH3CHRNA7LOXL2CHRM5
SCHEMBL28753740 0.85 SIGMAR1 (0.62) TAAR1HRH3CHRNA7LOXL2HRH1
SCHEMBL18762839 0.82 HRH3 (0.84) TAAR1HRH3CHRNA7CYP1A2CYP2C19
SCHEMBL4001727 0.80 KDM4E (0.47) CHRNA7LOXL2CYP1A2CYP3A4CYP2D6
SCHEMBL3995171 0.79 SIGMAR1 (0.46) CHRNA7LOXL2CYP1A2CYP3A4CYP2D6
SCHEMBL6430952 0.79 SIGMAR1 (0.49) HRH3CHRNA7LOXL2CYP1A2CYP3A4
SCHEMBL17886874 0.79 LOXL2 (0.43) TAAR1HRH3CHRNA7LOXL2CYP1A2
SCHEMBL3031908 0.77 LOXL2 (0.46) HRH3LOXL2CYP1A2CYP3A4CYP2D6
SCHEMBL6826869 0.77 CYP1A2 (0.42) TAAR1HRH3CHRNA7LOXL2CYP1A2
SCHEMBL4447413 0.77 CYP1A2 (0.42) TAAR1HRH3CHRNA7LOXL2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118834490-A Photo-crosslinkable perfluorinated ion membrane and preparation method thereof 上海交通大学 2024-10-25 CN claimed
US-4402843-A Viscosity index improvers with dispersant properties prepared by reaction of lithiated hydrogenated copolymers with 4-substituted aminopyridines PHILLIPS PETROLEUM COMPANY (US) 1983-09-06 US claimed
CN-118834490-A Photo-crosslinkable perfluorinated ion membrane and preparation method thereof 上海交通大学 2024-10-25 CN disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-08-10 US disclosed
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 EP disclosed
US-20160185780-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-06-30 US disclosed
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-02 US disclosed
US-9193752-B2 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom ISIS PHARMACEUTICALS, INC. (US) 2015-11-24 US disclosed
WO-2014210159-A1 METHODS OF MODULATING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2014-12-31 WO disclosed
EP-2314594-B1 6-modified bicyclic nucleic acid analogs ISIS PHARMACEUTICALS INC (US) 2014-07-23 EP disclosed
US-20060178360-A1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LABORATOIRES FOURNIER S.A. (FR) 2006-08-10 US disclosed
CN-1764661-A Benzenesulfonamide derivatives, process for their preparation and their use for the treatment of pain FOURNIER LAB SA (FR) 2006-04-26 CN disclosed
EP-1606288-A1 BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN LABORATOIRES FOURNIER S.A. (FR) 2005-12-21 EP disclosed
WO-2004087700-A1 BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN LABORATOIRES FOURNIER S.A. (FR) 2004-10-14 WO disclosed
US-20040009938-A1 Methods of enhancing renal uptake of oligonucleotides ISIS PHARMACEUTICAL INC. 2004-01-15 US disclosed
US-6673912-B1 2′-O-aminoethyloxyethyl-modified oligonucleotides ISIS PHARMACEUTICALS, INC. 2004-01-06 US disclosed
US-6600032-B1 Compound for use in the treatment of viral, protozoan and parasitic infections ISIS PHARMACEUTICALS, INC. 2003-07-29 US disclosed
US-4546176-A 7-Carboxymethoxyphenylacetamido-3-cephem derivatives and antibacterial preparations containing the same EISAI CO., LTD. (JP) 1985-10-08 US disclosed
US-4402843-A Viscosity index improvers with dispersant properties prepared by reaction of lithiated hydrogenated copolymers with 4-substituted aminopyridines PHILLIPS PETROLEUM COMPANY (US) 1983-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185780-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 TAAR1 1344/4885HRH3 1610/4885CHRNA7 2234/4885
US-20060178360-A1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LTB4R2, BDKRB2, TBXA2R TAAR1 2722/4885HRH3 863/4885CHRNA7 1687/4885
US-20160151335-A1 METHODS OF MODULATING CFTR ACTIVITY CFTR, HSP90B1, SERPINB1 TAAR1 4242/4885HRH3 3764/4885CHRNA7 2885/4885
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 TAAR1 1344/4885HRH3 1610/4885CHRNA7 2234/4885
US-20040009938-A1 Methods of enhancing renal uptake of oligonucleotides NUDT1, SLC29A2, DUT TAAR1 4217/4885HRH3 1143/4885CHRNA7 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.